14.21
1.65%
0.23
Neogenomics Inc stock is traded at $14.21, with a volume of 885.14K.
It is up +1.65% in the last 24 hours and down -19.03% over the past month.
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
See More
Previous Close:
$13.98
Open:
$14.12
24h Volume:
885.14K
Relative Volume:
1.16
Market Cap:
$1.82B
Revenue:
$628.25M
Net Income/Loss:
$-78.55M
P/E Ratio:
-22.92
EPS:
-0.62
Net Cash Flow:
$-29.73M
1W Performance:
-3.79%
1M Performance:
-19.03%
6M Performance:
-8.32%
1Y Performance:
-8.09%
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
14.21 | 1.82B | 628.25M | -78.55M | -29.73M | -0.62 |
TMO
Thermo Fisher Scientific Inc
|
559.65 | 214.07B | 42.37B | 6.14B | 7.78B | 15.95 |
DHR
Danaher Corp
|
238.36 | 172.16B | 23.74B | 3.89B | 4.98B | 5.24 |
A
Agilent Technologies Inc
|
147.36 | 42.09B | 6.51B | 1.29B | 1.37B | 4.42 |
IQV
Iqvia Holdings Inc
|
197.36 | 35.82B | 15.32B | 1.41B | 1.96B | 7.62 |
IDXX
Idexx Laboratories Inc
|
419.26 | 34.33B | 3.84B | 866.24M | 792.60M | 10.37 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-13-25 | Downgrade | The Benchmark Company | Buy → Hold |
Dec-10-24 | Initiated | Jefferies | Buy |
May-01-24 | Resumed | Craig Hallum | Buy |
Dec-29-23 | Reiterated | BTIG Research | Buy |
Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
Feb-01-23 | Upgrade | Needham | Hold → Buy |
Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
Aug-22-22 | Downgrade | Needham | Buy → Hold |
Jun-03-22 | Initiated | Piper Sandler | Overweight |
Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
Jan-18-22 | Resumed | Stephens | Overweight |
Dec-16-21 | Initiated | Cowen | Outperform |
Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jun-03-21 | Initiated | Goldman | Buy |
Feb-25-21 | Resumed | Needham | Buy |
Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
Jan-28-21 | Initiated | Truist | Buy |
Dec-11-20 | Resumed | BTIG Research | Buy |
Oct-28-20 | Reiterated | Needham | Buy |
Sep-09-20 | Initiated | Morgan Stanley | Overweight |
Aug-28-20 | Initiated | Guggenheim | Buy |
Jul-29-20 | Reiterated | Needham | Buy |
Jun-25-20 | Initiated | BofA/Merrill | Buy |
Apr-21-20 | Resumed | Stephens | Overweight |
Mar-02-20 | Resumed | Craig Hallum | Buy |
Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
Oct-30-19 | Reiterated | Needham | Buy |
May-01-19 | Reiterated | Needham | Buy |
Mar-29-19 | Reiterated | Needham | Buy |
Jan-03-19 | Initiated | Needham | Buy |
Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
Aug-21-18 | Initiated | Leerink Partners | Outperform |
May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
Aug-24-17 | Initiated | Gabelli & Co | Buy |
Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
Brokerages Set NeoGenomics, Inc. (NASDAQ:NEO) PT at $20.30 - MarketBeat
Benchmark retains Hold on Neogenomics stock, raises 2025 revenue forecast - MSN
NeoGenomics (NEO) Surges 9.1%: Is This an Indication of Further Gains? - MSN
Benchmark retains Hold on Neogenomics stock, raises 2025 revenue forecast By Investing.com - Investing.com Canada
Neogenomics stock sees solid support from Needham on updated guidance and expansion plans - Investing.com Canada
NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance - Yahoo! Voices
Medtech Surges, Reversing CEO-Tied Selloff, On Long-Term Guide - Investor's Business Daily
NEONeoGenomics, Inc. Latest Stock News & Market Updates - StockTitan
5 Analysts Assess NeoGenomics: What You Need To Know - Benzinga
NeoGenomics (NASDAQ:NEO) Shares Gap UpStill a Buy? - MarketBeat
NeoGenomics rises on upbeat sales outlook for 2025 - MSN
NeoGenomics stock rises on upbeat 2025 financial outlook By Investing.com - Investing.com Nigeria
NeoGenomics stock rises on upbeat 2025 financial outlook - Investing.com
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Benzinga
NeoGenomics Announces Executive Bonuses and Revenue Growth - TipRanks
NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan - The Bakersfield Californian
NeoGenomics Projects Strong Growth: 43-51% EBITDA Jump, $735M+ Revenue Target for 2025 - StockTitan
Adaptive, NeoGenomics partner to expand access to disease monitoring - MSN
Adaptive Biotechnologies and NeoGenomics Partner to Expand - GlobeNewswire
Adaptive Biotechnologies and NeoGenomics partner to expand access to disease monitoring for blood cancer patients - Seeking Alpha
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients - The Manila Times
Adaptive Biotech Partners with NeoGenomics to Transform Blood Cancer Testing with clonoSEQ - StockTitan
What You Can Learn From NeoGenomics, Inc.'s (NASDAQ:NEO) P/S After Its 29% Share Price Crash - Simply Wall St
NeoGenomics (NASDAQ:NEO) Sets New 52-Week LowWhat's Next? - MarketBeat
NeoGenomics Inc (NEO) Trading Down 14.52% on Jan 13 - GuruFocus.com
NeoGenomics (NASDAQ:NEO) Trading Down 8%Here's What Happened - MarketBeat
NeoGenomics (NASDAQ:NEO) Downgraded by Benchmark to Hold - MarketBeat
NeoGenomics price target lowered to $18 from $21 at BTIG - MSN
NeoGenomics CEO Chris Smith to retire - MSN
NeoGenomics announces CEO succession plan - Gulfshore Business
NeoGenomics CEO change prompts Raymond James to hold rating By Investing.com - Investing.com Canada
Neogenomics stock holds $19 target despite CEO change By Investing.com - Investing.com UK
NeoGenomics CEO steps down, shares fall 17% By Investing.com - Investing.com Canada
NeoGenomics Shares Fall on CEO's Plan to Retire - MarketWatch
NeoGenomics' (NEO) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
NeoGenomics (NEO) Shares Cross Below 200 DMA - Nasdaq
NeoGenomics Shares Are Falling Today: What's Going On? - Benzinga
NeoGenomics (NASDAQ:NEO) Shares Gap DownWhat's Next? - MarketBeat
NeoGenomics (NASDAQ:NEO) Releases FY 2024 Earnings Guidance - MarketBeat
NeoGenomics (NEO) CEO Chris Smith to retire - StreetInsider.com
NeoGenomics, Inc. Reaffirms Earnings Guidance for Full Year Ended December 31, 2024 - Marketscreener.com
NeoGenomics Appoints Tony Zook As CEO - citybiz
NeoGenomics CEO Chris Smith to Retire; Tony Zook to Take Helm - MarketWatch
NeoGenomics Announces CEO Transition and Leadership Change - TipRanks
NeoGenomics Announces Chief Executive Officer Succession - The Bakersfield Californian
Neogenomics, Announces Retirement of Chris Smith as Board Member, Effective April 1, 2025 - Marketscreener.com
FY2024 EPS Estimates for NeoGenomics Increased by Analyst - MarketBeat
NeoGenomics (NASDAQ:NEO) Sets New 12-Month HighShould You Buy? - MarketBeat
NeoGenomics stock hits 52-week high at $19.01 amid growth By Investing.com - Investing.com Australia
NeoGenomics stock hits 52-week high at $19.01 amid growth - Investing.com
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):